Anzibel is a combined antiseptic preparation for topical use in the oropharyngeal zone. the pharmacological effect is due to the components that make up the preparation.
Chlorhexidine has a bacteriostatic effect at low concentrations and bactericidal at high concentrations. The mechanism of action of chlorhexidine is the formation of bonds with the cell membrane of bacteria, which leads to a violation of their structure. It is active against staphylococci, streptococci, Candida albicans, Escherichia coli and some aerobic and anaerobic bacteria. Proteus, Pseudomonas, Klebsiella spp are weakly sensitive to chlorhexidine.
Benzocaine has a local anesthetic effect in the presence of severe pain syndrome. It is used to treat wounds of the mucous membrane of the oral cavity and pharynx.
Enoxolone is characterized by anti-inflammatory and analgesic properties, as well as a pronounced antiviral effect against viruses containing DNA or RNA, as well as various strains of Herpes simplex and Herpes zoster viruses.
1 lozenge contains chlorhexidine hydrochloride 5 mg, benzocaine 4 mg, enoxolone 3 mg
Excipients:
lozenges: sorbitol (E 420), potassium acesulfame, magnesium stearate.
menthol flavored lozenges: sorbitol (E 420), potassium acesulfame, magnesium stearate, menthol flavor.
lozenges with honey and lemon flavor: sorbitol (E 420), potassium acesulfame, magnesium stearate, lemon flavoring, honey flavoring.
Lozenges.
Basic physical and chemical properties: round, biconvex pastilles of white or almost white color, smooth on one side and with the “ŋ” logo on the other;
round, biconvex pastilles of white or almost white color, with a menthol scent, smooth on one side and with the “ŋ” logo on the other;
round, biconvex pastilles of white or almost white color with the smell of lemon and honey, smooth on one side and with the “ŋ” logo on the other.
Symptomatic treatment for infectious and inflammatory diseases of the oral cavity and pharynx.
Hypersensitivity to the active ingredients of the preparation or known hypersensitivity to other anesthetics, derivatives of esters, exhibiting this type of activity. Phenylketonuria.
Interaction with other medicinal products and other forms of interaction
Do not use with other medicines containing antiseptics.
Simultaneous use with preparations containing iodine is not recommended.
The benzocaine contained in the preparation interacts with cholinesterase inhibitors (inhibits the metabolism of local anesthetics, there is an increased risk of systemic toxicity), sulfonamides (benzocaine metabolites can suppress the antibacterial activity of sulfonamides).
The simultaneous use of enoxolone and hydrocortisone can potentiate the effect of the latter on the skin.
Interaction with diagnostic tests.
Interactions with diagnostic tests (benthromide) used to assess pancreatic function may occur. The results are not validated because benzocaine is metabolized by arylamines and also increases the amount of para-aminobenzoic acid (PABA). It is recommended to stop treatment at least 3 days before the test.
Do not exceed the recommended dose.
During the use of local anesthetics, including benzocaine, there is an increased risk of systemic toxicity in elderly patients, with acute illness or in debilitated patients. When using enoxolol in elderly patients in high doses or with prolonged use, fluid retention, edema and arterial hypertension are possible.
Patients with poor tolerance to ester-type local anesthetics (especially para-aminobenzoic acid (PABA) derivatives, parabens, or paraphenylenediamine (hair dye)) may also have poor tolerance to benzocaine.
When using the preparation, it is necessary to assess the benefit / risk ratio in situations such as severe damage to the oral mucosa (increased absorption of anesthetics).
On the surfaces of fillings or their uneven edges, irreversible staining is possible due to the action of chlorhexidine.
The preparation contains benzocaine, which can lead to a positive doping test in athletes.
Anzibel contains sorbitol, so it is not recommended for patients with hereditary fructose intolerance.
Anzibela contains acesulfame potassium, this should be taken into account in patients with impaired renal function or patients on a potassium-controlled diet.
Since the preparation contains acesulfame potassium, there is a risk of an increase in the level of potassium in the stomach in patients with insufficient absorption of potassium. An increase in potassium levels can cause stomach irritation and diarrhea.
In patients with periodontitis, chlorhexidine may contribute to an increase in supragingival dental plaque.
Careful oral hygiene should be performed using dental calculus toothpastes to prevent plaque buildup and chlorhexidine staining of teeth.
Use during pregnancy and lactation.
Anzibel should not be used during pregnancy.
Enoxolone, when used in high doses and at doses above 60 mg / day, and long-term use, can contribute to fluid retention, edema and hypertension, this should be taken into account in pregnant women.
There is no data on the use of chlorhexidine and benzocaine in pregnant women.
It is not known whether the active components of the preparation penetrate into breast milk, so the preparation should not be used during breastfeeding.
The ability to influence the reaction rate when driving or operating other mechanisms.
Does not affect.
Lozenges are used in the oral cavity until completely absorbed.
Recommended doses for adults and children over 12 years of age: 1 lozenge at intervals of 2-3 hours (maximum daily dose - 8 lozenges).
Apply after meals and after brushing your teeth.
It is recommended not to rinse your mouth or drink liquids within 2 hours after the lozenges have been absorbed.
The duration of treatment depends on the course of the disease and is usually 3 to 7 days, but if the symptoms of the disease persist or worsen 2 days after starting the use of the preparation, you should consult a doctor.
Children.
The efficacy and safety of using Anzibel in children under 12 years of age have not been established, therefore, the preparation should not be prescribed to this age group of patients.
Overdose is unlikely.
In case of an overdose of enoxolone, hypermineralcorticoidism, sodium retention and potassium loss, edema, increased blood pressure and inhibition of the renin-angiotensin-aldosterone system may occur.
In case of an overdose of chlorhexedine, especially in children, symptoms of alcohol poisoning (confusion, numbness, or unsteady gait) are noted.
Despite the low absorption of benzocaine, its excessive content can cause systemic absorption, the symptoms of which may be blurred vision, diplopia, dizziness, convulsions, tinnitus, agitation (CNS stimulation), which is replaced by drowsiness (CNS depression), increased sweating, decreased arterial pressure, slowing heart rate and heart rhythm disturbances, suppression of the cardiovascular system.
Treatment of chlorhexedine overdose is symptomatic. Treatment includes oxygen as needed or artificial respiration. For the treatment of circulatory depression syndrome, the use of vasoconstrictors and the use of fluids are necessary. Patients may experience methemoglobinemia (shortness of breath, dizziness, weakness, fatigue, lethargy), in which case methylene blue should be used.
From the immune system: allergic reactions, including nasal congestion.
On the part of the skin and subcutaneous tissue: itching, urticaria, skin rash, contact dermatitis.
From the side of the cardiovascular system: with prolonged use, edema, arterial hypertension may occur.
From the digestive system: changes in taste, plaque, discoloration / pigmentation of tooth enamel (brown spots), fillings and dentures; mumps, stomach irritation, diarrhea, tongue and mouth soreness, mouth and tongue irritation or inflammation, and burning, itching, swelling, or redness in or around the mouth.
3 years.
Store at a temperature not exceeding 25 ° C in its original packaging.
Keep out of the reach of children.
There are no reviews for this product.